Correlation Between Xvivo Perfusion and SpectraCure

Can any of the company-specific risk be diversified away by investing in both Xvivo Perfusion and SpectraCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xvivo Perfusion and SpectraCure into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Xvivo Perfusion AB and SpectraCure AB, you can compare the effects of market volatilities on Xvivo Perfusion and SpectraCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xvivo Perfusion with a short position of SpectraCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xvivo Perfusion and SpectraCure.

Diversification Opportunities for Xvivo Perfusion and SpectraCure

0.79

Correlation Coefficient

Xvivo Perfusion  SpectraCure

Poor diversification

The 3 months correlation between Xvivo and SpectraCure is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Xvivo Perfusion AB and SpectraCure AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SpectraCure AB and Xvivo Perfusion is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xvivo Perfusion AB are associated (or correlated) with SpectraCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SpectraCure AB has no effect on the direction of Xvivo Perfusion i.e., Xvivo Perfusion and SpectraCure go up and down completely randomly.

Pair Corralation between Xvivo Perfusion and SpectraCure

Assuming the 90 days trading horizon Xvivo Perfusion AB is expected to generate 0.44 times more return on investment than SpectraCure. However, Xvivo Perfusion AB is 2.27 times less risky than SpectraCure. It trades about -0.05 of its potential returns per unit of risk. SpectraCure AB is currently generating about -0.14 per unit of risk. If you would invest  52,300  in Xvivo Perfusion AB on September 2, 2024 and sell it today you would lose (4,300) from holding Xvivo Perfusion AB or give up 8.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Xvivo Perfusion AB  vs.  SpectraCure AB

Xvivo Perfusion AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Xvivo Perfusion AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

SpectraCure AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days SpectraCure AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Xvivo Perfusion and SpectraCure

The main advantage of trading using opposite Xvivo Perfusion and SpectraCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xvivo Perfusion position performs unexpectedly, SpectraCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SpectraCure will offset losses from the drop in SpectraCure's long position.

The idea behind Xvivo Perfusion AB and SpectraCure AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.